Whitehawk Therapeutics (WHWK)
Develops in-licensed antibody-drug conjugates for cancer treatment.
Something off on this page? Send us feedback.
Develops three in-licensed ADC candidates for cancer treatment: PTK7-targeted HWK-007, MUC16-targeted HWK-016, and SEZ6-targeted HWK-206. Having sold FYARRO, it is focused on clinical development, with progress tied to FDA clearance, trial execution, and manufacturing.
Develops antibody-drug conjugates, or ADCs, for cancer treatment. Its portfolio includes PTK7-targeted HWK-007, MUC16-targeted HWK-016, and SEZ6-targeted HWK-206, all in-licensed from WuXi Biologics. The candidates address established tumor targets under a global development and commercialization license from WuXi Biologics.
HWK-007 and HWK-016 are in actively recruiting Phase 1 trials, while HWK-206 was expected to enter IND review in mid-2026. After selling the FYARRO business, it focuses on clinical development rather than commercial operations.
The operating model depends on FDA clearance, trial execution, and manufacturing and IND-enabling studies proceeding on schedule.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $190.0M · Total debt $0 · Total assets $194.0M · Shareholders' equity $182.9M
- Revenue
- $0
- Operating income
- −$18.1M
- Net income
- −$16.6M
No dividends on record.
| Insiders5 holders · as of May 18, 2026 | — | 1.65M shares | |
| Strategic holders1 holder · as of Mar 11, 2025 | — | 4.73M shares |
No reliable share count is available for this listing, so stakes are shown as shares, not percentages.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Suvretta Capital Management, LLCStrategic | — | 4.73M | 13Gfiled Mar 11, 2025 ↗ |
OrbiMed Advisors LLCInstitution | — | 4.17M | 13Gfiled May 15, 2025 ↗ |
Coastlands Capital LPInstitution | — | 2.82M | 13Gfiled Aug 25, 2025 ↗ |
David James LennonInsiderdirector, officer: CHIEF EXECUTIVE OFFICER | — | 569,643 | Form 4filed May 18, 2026 ↗ |
Bryan BallInsiderofficer: See remarks | — | 448,126 | Form 4filed May 18, 2026 ↗ |
| See all 10 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 16, 2026 | Scott M. Giacobello | officer: CHIEF FINANCIAL OFFICER | −141,600 | $4.13 |
| Apr 15, 2026 | Scott M. Giacobello | officer: CHIEF FINANCIAL OFFICER | −77,000 | $3.86 |
| Apr 14, 2026 | Bryan Ball | officer: See remarks | −92,460 | $3.64 |
| Apr 13, 2026 | Bryan Ball | officer: See remarks | −26,389 | $3.46 |
| Apr 10, 2026 | Bryan Ball | officer: See remarks | −6,596 | $3.43 |
- Eli Lilly
Phase 1 PTK7 ADC rival in lung and endometrial cancer
- ArriVent BioPharma
IND-cleared MUC16/NaPi2b ADC rival in ovarian and endometrial cancer
- AbbVie
Clinical-stage SEZ6 ADC rival for small-cell lung cancer
- Regeneron
MUC16-targeted immunotherapy rival in ovarian cancer
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Whitehawk Therapeutics | $4.64 | −1.59% | $268.5M | — | — | — | — |
| Eli Lilly | $1,164.00 | +0.40% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| ArriVent BioPharma | $31.35 | +2.85% | $1.42B | — | — | — | — |
| AbbVie | $262.35 | +0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Regeneron | $845.50 | −0.77% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Median | 38.9 | 17.2 | 7.2 | +16.7% |